{"id":"W4410050643","doi":"10.1093/bjd/ljaf156","title":"Efficacy and safety of rilzabrutinib in patients with moderate-to-severe atopic dermatitis: 16-week results from a proof-of-concept phase II clinical trial","year":2025,"lang":"en","type":"article","venue":"British Journal of Dermatology","topic":"Dermatology and Skin Diseases","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Probity Medical Research","funders":"Sanofi","keywords":"Medicine; Atopic dermatitis; Eczema Area and Severity Index; Placebo; Clinical endpoint; Adverse effect; Internal medicine; Regimen; Dermatology Life Quality Index; Clinical trial; Randomized controlled trial; Dermatology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004614531,0.001650717,0.002562544,0.000298086,0.000427683,0.001440136,0.00114647,0.001846064,0.005044088],"category_scores_gemma":[0.00176238,0.0006027592,0.002469404,0.0003327673,0.0008298774,0.001164471,0.0004898935,0.004028294,0.001340842],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008886632,"about_ca_system_score_gemma":0.001235108,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003327679,"about_ca_topic_score_gemma":0.000992685,"domain_scores_codex":[0.9992981,0.0003098438,0.0000587912,0.0001089648,0.00009540041,0.0001287712],"domain_scores_gemma":[0.9987869,0.0002140005,0.0003337172,0.0001158424,0.0001049487,0.0004446134],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7919173,0.04813391,0.004806852,0.003280398,0.003175261,0.0002537501,0.0002942494,0.001678913,0.04322855,0.0002488711,0.00608052,0.09690133],"study_design_scores_gemma":[0.7759939,0.2082498,0.009005357,0.0001455602,0.0008908188,0.0002816896,0.0000350604,0.0005616921,0.001808969,0.0002051354,0.002791584,0.00003043124],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9723572,0.0133808,0.001093229,0.001246023,0.0003382121,0.005865646,0.002226533,0.0002089762,0.003283424],"genre_scores_gemma":[0.977756,0.005631033,0.002771669,0.001855363,0.0003812316,0.005770234,0.002141044,0.00003965007,0.003653685],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005044088,"threshold_uncertainty_score":0.02440429,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01982358497355226,"score_gpt":0.3147354051382038,"score_spread":0.2949118201646516,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}